Cynthia Aranow
Northwell Health · Feinstein Institute for Medical Research, Northwell Health · Feinstein Institute for Medical Research
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Cynthia Aranow as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06987565 · Transcutaneous Vagus Nerve Stimulation in SLENorthwell Health · recruiting · Systemic Lupus Erythematosus · principal investigator
- Ph2NCT05710640 · Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIANational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Juvenile Idiopathic Arthritis (JIA) · study chair
- Ph4NCT03543839 · Trial of Belimumab in Early LupusNorthwell Health · recruiting · Lupus Erythematosus, Systemic, Lupus Erythematosus · principal investigator
- N/ANCT02910973 · Using a Transcutaneous Electrical Auricular Stimulator to Harness the Cholinergic Anti-Inflammatory PathwayNorthwell Health · completed · Healthy Volunteers · principal investigator
- N/ANCT02822989 · Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal PainNorthwell Health · completed · Lupus Erythematosus, Systemic, Musculoskeletal Pain · principal investigator
- Ph2NCT02260934 · Rituximab and Belimumab for Lupus NephritisNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Lupus Nephritis · study chair
- N/ANCT00908986 · Open Label Pilot Trial of Rituximab in Lupus Membranous NephritisNorthwell Health · withdrawn · Lupus Nephritis · principal investigator
- Ph2NCT00710021 · Vitamin D3 in Systemic Lupus ErythematosusNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Systemic Lupus Erythematosus, SLE, Lupus · study chair
- Ph2NCT00302952 · Lovastatin for the Treatment of Mildly Active Rheumatoid ArthritisNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Rheumatoid Arthritis · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical CoreP01AI073693 · NIAID · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · fiscal years 2025 to 2026 · $142,582 awarded in 2026Same name and institution; not confirmed by an ID
- Core B: Clinical CoreP01AI172523 · NIAID · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · fiscal years 2024 · $325,335 awarded in 2024Same name and institution; not confirmed by an ID
- Novel Nontoxic Therapeutic Interventions for Autoimmune Inflammatory DiseaseUM1AI110494 · NIAID · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · fiscal years 2014 to 2023 · $83,750 awarded in 2023Same name and institution; not confirmed by an ID
- CLINICAL TRIAL: A DOUBLE BLIND, PLACEBO CONTROLLED, PHASE II, RANDOMIZED STUDY OM01RR018535 · NCRR · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · fiscal years 2008 to 2010 · $13,141 awarded in 2010Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:33 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.N Engl J Med · 2005808 citationsRCR 21.3
- Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.Arthritis Rheum · 2012334 citationsRCR 9.0
- 204 citationsRCR 6.5
- Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.Arthritis Rheum · 2010189 citationsRCR 4.4
- Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.Arthritis Rheumatol · 2021167 citationsRCR 10.5
- 146 citationsRCR 3.7
- Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial.Ann Rheum Dis · 2021143 citationsRCR 10.6
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.Arthritis Rheumatol · 2016105 citationsRCR 3.9
- An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA.Ann Rheum Dis · 201193 citationsRCR 3.0
- Treatment of systemic lupus erythematosus with LJP 394.J Rheumatol · 200190 citationsRCR 2.1